4D Molecular Therapeutics, Inc.
FDMT
$3.09
-$0.04-1.28%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 1,300.00% | -66.67% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 1,300.00% | -66.67% | |||
| Cost of Revenue | -5.54% | 11.96% | |||
| Gross Profit | 5.57% | -11.97% | |||
| SG&A Expenses | -0.73% | 3.00% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -4.42% | 9.74% | |||
| Operating Income | 4.45% | -9.75% | |||
| Income Before Tax | 3.42% | -13.29% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 3.42% | -13.29% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 3.42% | -13.29% | |||
| EBIT | 4.45% | -9.75% | |||
| EBITDA | 4.45% | -10.17% | |||
| EPS Basic | 3.60% | -13.11% | |||
| Normalized Basic EPS | 3.58% | -13.12% | |||
| EPS Diluted | 3.60% | -13.11% | |||
| Normalized Diluted EPS | 3.58% | -13.12% | |||
| Average Basic Shares Outstanding | 0.18% | 0.16% | |||
| Average Diluted Shares Outstanding | 0.18% | 0.16% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||